Trial Profile

Erlotinib Prevention of Oral Cancer (EPOC).

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 22 Apr 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Erlotinib (Primary)
Indications Mouth neoplasm
Focus Therapeutic Use
Acronyms EPOC

Most Recent Events

10 Jan 2019 Status changed from active, no longer recruiting to completed.
25 Sep 2017 Planned primary completion date changed from 1 Nov 2018 to 1 Nov 2019.
02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com